# Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease (AD) in Comparison to Healthy Volunteers

> **NCT03417986** · PHASE2 · COMPLETED · sponsor: **Immungenetics AG** · enrollment: 20 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** TEP

## Key facts

- **NCT ID:** NCT03417986
- **Lead sponsor:** Immungenetics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-24
- **Primary completion:** 2021-07-12
- **Final completion:** 2021-10-22
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03417986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03417986, "Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease (AD) in Comparison to Healthy Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03417986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*